Surlorian

N/A

Report date: 2026/05/06 20:02:28
NME

Base Information

Drug NameSurlorian
Drug Alias NameARM-210S-48168
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRyanodine receptor calcium release channel modulators
TargetsRyanodine receptor calcium release channel
Therapy Area/IndicationsAutosomal Dominant RYR1-Related MyopathyTachycardia, Ventricular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsGermany +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArmgo Pharma
China Registration ClassN/A

Develop Information

Active CompaniesRyCarma Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutosomal Dominant RYR1-Related Myopathy
Inactive IndicationsTachycardia, Ventricular

Other Information

ATC CodeN/A
Related LinksN/A